1-10 of 10
Sylvie Laquerre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity

Open Access
Dirk Brehmer, Lijs Beke, Tongfei Wu, Hillary J. Millar, Christopher Moy, Weimei Sun, Geert Mannens, Vineet Pande, An Boeckx, Erika van Heerde, Thomas Nys, Emmanuel M. Gustin, Bie Verbist, Longen Zhou, Yue Fan, Vipul Bhargava, Pegah Safabakhsh, Petra Vinken, Tinne Verhulst, Angelique Gilbert, Sumit Rai, Timothy A. Graubert, Friederike Pastore, Danilo Fiore, Junchen Gu, Amy Johnson, Ulrike Philippar, Barbara Morschhäuser, David Walker, Desiree De Lange, Vikki Keersmaekers, Marcel Viellevoye, Gaston Diels, Wim Schepens, Jan Willem Thuring, Lieven Meerpoel, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2317–2328.
https://doi.org/10.1158/1535-7163.MCT-21-0367
Published: 01 December 2021
View article titled, Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
Open the PDF for Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis

Free
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre, Sheri L. Moores
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (10): 2044–2056.
https://doi.org/10.1158/1535-7163.MCT-20-0071
Published: 02 October 2020
View article titled, Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Open the PDF for Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis in another window
Includes: Multimedia, Supplementary data
Journal Articles

Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance

Free
Kristina B. Emdal, Antje Dittmann, Raven J. Reddy, Rebecca S. Lescarbeau, Sheri L. Moores, Sylvie Laquerre, Forest M. White
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (11): 2572–2585.
https://doi.org/10.1158/1535-7163.MCT-17-0413
Published: 01 November 2017
View article titled, Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
Open the PDF for Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance in another window
Includes: Supplementary data
Journal Articles

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Free
Timothy P.S. Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Tinne Verhulst, Caroline Paulussen, Kelly Van De Ven, Peter King, Eddy Freyne, David C. Rees, Matthew Squires, Gordon Saxty, Martin Page, Christopher W. Murray, Ron Gilissen, George Ward, Neil T. Thompson, David R. Newell, Na Cheng, Liang Xie, Jennifer Yang, Suso J. Platero, Jayaprakash D. Karkera, Christopher Moy, Patrick Angibaud, Sylvie Laquerre, Matthew V. Lorenzi
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (6): 1010–1020.
https://doi.org/10.1158/1535-7163.MCT-16-0589
Published: 01 June 2017
View article titled, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Open the PDF for Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor in another window
Includes: Supplementary data
Journal Articles

Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

Free
Junping Jing, Joel Greshock, Joanna Dawn Holbrook, Aidan Gilmartin, Xiping Zhang, Elizabeth McNeil, Theresa Conway, Christopher Moy, Sylvie Laquerre, Kurt Bachman, Richard Wooster, Yan Degenhardt
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 720–729.
https://doi.org/10.1158/1535-7163.MCT-11-0505
Published: 06 March 2012
View article titled, Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Open the PDF for Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212 in another window
Includes: Supplementary data
Journal Articles

Abstract B71: Acquired resistance to the BRAF inhibitor GSK2118436, mediated by NRAS or MEK mutation, can be overcome with combinations that inhibit BRAF and MEK, BRAF and PI3K/mTOR, or MEK and PI3K/mTOR.

Free
James G. Greger, Jr., Stephen D. Eastman, Vivian Zhang, Maureen R. Bleam, Ashley Hughes, Kimberly N. Smitheman, Sylvie Laquerre, Li Liu, Tona M. Gilmer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B71.
https://doi.org/10.1158/1535-7163.TARG-11-B71
Published: 12 November 2011
View article titled, Abstract B71: Acquired resistance to the BRAF inhibitor GSK2118436, mediated by NRAS or MEK mutation, can be overcome with combinations that inhibit BRAF and MEK, BRAF and PI3K/mTOR, or MEK and PI3K/mTOR.
Journal Articles

Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

Free
Yan Degenhardt, Joel Greshock, Sylvie Laquerre, Aidan G. Gilmartin, Junping Jing, Mark Richter, Xiping Zhang, Maureen Bleam, Wendy Halsey, Ashley Hughes, Christopher Moy, Nancy Liu-Sullivan, Scott Powers, Kurtis Bachman, Jeffrey Jackson, Barbara Weber, Richard Wooster
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 2079–2089.
https://doi.org/10.1158/1535-7163.MCT-10-0095
Published: 07 July 2010
View article titled, Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability
Open the PDF for Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability in another window
Includes: Supplementary data
Journal Articles

Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation

Free
Sylvie Laquerre, Marc Arnone, Katherine Moss, Jingsong Yang, Kelly Fisher, Laurie S. Kane‐Carson, Kimberly Smitheman, Jessica Ward, Bradley Heidrich, Tara Rheault, George Adjabeng, Keith Hornberger, John Stellwagen, Alex Waterson, Chao Han, Robert A. Mook, Jr., David Uehling, Alastair J. King
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B88.
https://doi.org/10.1158/1535-7163.TARG-09-B88
Published: 10 December 2009
View article titled, Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B‐RafV600E mutation
Journal Articles

Association of mutations in the TP53 gene and chromosome instability with sensitivity to the PLK1 inhibitor GSK461364

Free
Richard Wooster, Yan Degenhardt, Joel Greshock, Sylvie Laquerre, Aidan Gilmartin, Kurt Auger, Junping Jing, Ganesh Sathe, Barbara Weber, Jeff Jackson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C130.
Published: 01 November 2007
View article titled, Association of mutations in the TP53 gene and chromosome instability with sensitivity to the PLK1 inhibitor GSK461364
Journal Articles

A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A), demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro

Free
David Sutton, Aidan Gilmartin, Anna Kusnierz, Chiu-Mei Sung, Lusong Luo, Jeffrey Carson, Sylvie Laquerre, William Cornwell, Andrew King, Steven Knight, Dashyant Dhanak, Gustave Bergnes, Xiangping Qian, Penelope Chua, Kenneth Wood, Pearl Huang, Barbara Weber, Robert Copeland, Jeffrey Jackson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A111.
Published: 01 November 2007
View article titled, A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A), demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro